Although PD-1/PD-L1 blockades exhibit anti-tumor effects by activating the immune system, they also lead to an attack of the immune system on normal tissues, and these types of drug-related adverse reactions, mediated by immune mechanisms and which can involve different systems, are referred to as “immune-related adverse events (irAEs)”. Here, PDCD1 is linked to neoplasm.